<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recombinant human interleukin-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (rhIL-1ra) markedly protects against focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in the rat, implicating endogenous IL-1 in the events leading to <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The present experiments investigated the effect of intracerebroventricular (i.c.v.) administration of IL-1 beta or rhIL-1ra on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> damage and physiological parameters after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in the rat </plain></SENT>
<SENT sid="2" pm="."><plain>IL-1 beta (5 ng. i.c.v.) markedly (92%) enhanced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and caused a significant rise in body temperature, but rhIL-1ra (10 micrograms, i.c.v.) significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and did not significantly affect heart rate, blood pressure, or body temperature, rhIL-1ra administered 30 min before, or at the time of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in cortex (55 and 60%, respectively) and striatum (52 and 41%, respectively) </plain></SENT>
<SENT sid="3" pm="."><plain>rhIL-1ra administered 30 min after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> significantly reduced total and cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (26 and 29%, respectively), but did not significantly protect striatal tissue </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of rhIL-1ra were still evident in both cortex and striatum 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>These results support the role of IL-1 in ischaemic brain damage, revealing potent, sustained, neuroprotective effects of rhIL-1ra in the cortex and striatum, which cannot be attributed directly to changes in physiological parameters </plain></SENT>
</text></document>